Zai Lab (Shanghai) Co., Ltd. clinical trials

A subsidiary of Zai Lab Limited

The registry lists 25 studies whose lead sponsor is Zai Lab (Shanghai) Co., Ltd.. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.

Studies

Recruiting first, then most recently updated. Showing 25 of 25. All Zai Lab Limited studies →

• A Study of ZL-1310 in Subjects With Small Cell Lung CancerRecruitingNCT06179069Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)RecruitingNCT07218146Phase 3

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With SchizophreniaNot yet recruitingNCT07802132

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung CancerNot yet recruitingNCT07796100Phase 3

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study of ZL-1310 in Participants With Selected Solid TumorsRecruitingNCT06885281Phase 1/2

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy VolunteersNot yet recruitingNCT07658482Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07235384Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected TumorsRecruitingNCT07374848Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye DiseaseActive, not recruitingNCT07211776Phase 3

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Phase 2

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Phase 2

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer PatientsTerminatedNCT04212221Phase 1/2

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With MelanomaTerminatedNCT04653038Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid MalignanciesCompletedNCT05866354Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCActive, not recruitingNCT04262804Phase 2

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Trial of ZL-1201 in Subjects With Advanced CancerCompletedNCT04257617Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer PatientStatus unknownNCT03705156Phase 3

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid TumorsStatus unknownNCT05263986Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study of Niraparib in Patients With Relapsed Ovarian CancerCompletedNCT04392102Phase 2

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBCCompletedNCT04398108Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian CancerStatus unknownNCT03709316Phase 3

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT03516084Phase 3

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Phase 2

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.

• The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian CancerCompletedNCT03551171Phase 1

  Sponsor listed in the registry: Zai Lab (Shanghai) Co., Ltd.